Moderated by Corey Davis (LifeSci Advisors)
Join us for a virtual panel discussion with leading researchers and industry leaders who will share their perspectives and insights on recent developments in CRISPR technology, including successful collaborations between pharma and industry, safety concerns, IP development, entering the clinic, and more.
Dr. Lucas Harrington
Dr. Harrington is the co-founder and CSO of Mammoth Biosciences and a general partner for Scifounder Capital, a fund and incubator with the goal of helping more scientists start and build companies. Dr. Harrington co-founded Mammoth Biosciences with Jennifer Doudna, Janice Chen, and Trevor Martin with the goal of leveraging novel CRISPR systems to provide permanent cures for genetic diseases and to democratize disease detection. He conducted his undergraduate work at Washington University in St. Louis and Ph.D. at the University of California, Berkeley with Jennifer Doudna.
|
|
Dr. Brett Staahl
Dr. Staahl is co-founder and VP of Platform at Scribe Therapeutics. Prior to founding Scribe Therapeutics, Dr. Staahl was a research associate at Galileo Pharmaceuticals. He conducted his postdoc in Jennifer Doudna’s lab, focusing on how gene-editing, particularly CRISPR, could be used to treat Huntington’s disease. He received his B.A. in Molecular Biology from the University of Colorado, Boulder, and completed his Ph.D. in Developmental Biology at Stanford University in the lab of Prof. Gerald Crabtree.
|
|
Dr. Ayal Hendel
Dr. Hendel is a PI in the Faculty of Life Sciences at Bar-Ilan University, the Chair of the CRISPR-IL scientific committee and a member of the 8400 Health Network. His research focuses on developing genome editing as a curative therapy for childhood disorders and cancer immunotherapy. Dr. Hendel holds a B.A. in Biology from the Hebrew University, a M.Sc. and a Ph.D. from the Weizmann Institute of Science, and a postdoc form Stanford University.
|
|
Dr. Adi Barzel
Dr. Barzel is a senior lecturer at the Department of Biochemistry at Tel Aviv University and the President of the Israeli Society for Gene and Cell Therapy. Dr. Barzel is also the co-founder of LogicBio Therapeutics, a clinical stage public company developing genetic cures for congenital disorders, and the co-founder of Tabby Therapeutics engineering B cells for cancer immunotherapy.
|
|
Dr. Michal Golan -Mashiach
Dr. Golan-Mashiach is the founder and CEO of Edity Therapeutics and Applied Genomics. Edity reengineers immune cells to harness their power away from killing and to enable precise therapy. Dr. Golan-Mashiach has more than 25 years of an academic and industrial experience in drug development genetics, gene-editing, bioinformatics, and computational biology. She
holds a B.Sc. in Computer Science and MBA from Tel Aviv University, M.Sc. in Bioinformatics and Ph.D. in Systems-Biology from the Weizmann Institute of Science.
|
|
Dr. Gil Azulay
Dr. Azulay leads the hematology licensing and investments at Medison Ventures, the corporate arm of Medison Pharma. Before joining Medison, Dr. Azulay worked as a Senior Scientist at Trobix Bio, where he developed microbiome therapeutics based on CRISPR-armed bacteriophages. Dr. Azulay holds a M.SC. in molecular cell biology and Biotechnology, Ph.D. in Microbiology and Molecular Biology and an MBA from Tel Aviv University.
|
|
